DK3338791T3 - Terapeutisk dosering af en neuregulin i behandling eller profylaxis af hjertesvigt - Google Patents

Terapeutisk dosering af en neuregulin i behandling eller profylaxis af hjertesvigt Download PDF

Info

Publication number
DK3338791T3
DK3338791T3 DK17209369.2T DK17209369T DK3338791T3 DK 3338791 T3 DK3338791 T3 DK 3338791T3 DK 17209369 T DK17209369 T DK 17209369T DK 3338791 T3 DK3338791 T3 DK 3338791T3
Authority
DK
Denmark
Prior art keywords
neureguline
prophylaxis
treatment
heart failure
therapeutic dosage
Prior art date
Application number
DK17209369.2T
Other languages
Danish (da)
English (en)
Inventor
Anthony Caggiano
Anindita Ganguly
Jennifer Iaci
Tom Parry
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Application granted granted Critical
Publication of DK3338791T3 publication Critical patent/DK3338791T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK17209369.2T 2008-07-17 2009-07-17 Terapeutisk dosering af en neuregulin i behandling eller profylaxis af hjertesvigt DK3338791T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13517108P 2008-07-17 2008-07-17
EP09813336.6A EP2320933B1 (en) 2008-07-17 2009-07-17 Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure

Publications (1)

Publication Number Publication Date
DK3338791T3 true DK3338791T3 (da) 2019-12-16

Family

ID=42005671

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17209369.2T DK3338791T3 (da) 2008-07-17 2009-07-17 Terapeutisk dosering af en neuregulin i behandling eller profylaxis af hjertesvigt
DK09813336.6T DK2320933T3 (en) 2008-07-17 2009-07-17 THERAPEUTIC DOSAGE OF A NEUREGULIN OR A SUBSEQUENT THEREOF FOR TREATMENT OR PROPHYLAXY OF HEART FAILURE

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK09813336.6T DK2320933T3 (en) 2008-07-17 2009-07-17 THERAPEUTIC DOSAGE OF A NEUREGULIN OR A SUBSEQUENT THEREOF FOR TREATMENT OR PROPHYLAXY OF HEART FAILURE

Country Status (13)

Country Link
US (5) US20110166068A1 (OSRAM)
EP (3) EP2320933B1 (OSRAM)
JP (5) JP5797112B2 (OSRAM)
CN (3) CN104623633A (OSRAM)
AU (3) AU2009292216B2 (OSRAM)
BR (1) BRPI0916442A2 (OSRAM)
CA (1) CA2731113A1 (OSRAM)
DK (2) DK3338791T3 (OSRAM)
ES (2) ES2763184T3 (OSRAM)
MX (2) MX2011000696A (OSRAM)
PL (2) PL3338791T3 (OSRAM)
RU (4) RU2536938C2 (OSRAM)
WO (1) WO2010030317A2 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104623633A (zh) 2008-07-17 2015-05-20 阿索尔达治疗公司 用于治疗或预防心力衰竭的神经调节蛋白或其亚序列的治疗性施剂
RU2501564C2 (ru) 2008-08-15 2013-12-20 Акорда Терапьютикс, Инк. Композиции и способы для лечения во время не острых периодов после неврологического повреждения цнс
EP2808339B1 (en) * 2008-11-28 2017-02-15 Zensun (Shanghai) Science & Technology, Co., Ltd. Neuregulin peptides and their use
CN104984322B (zh) 2009-10-14 2020-09-11 阿寇达医疗有限公司 神经调节蛋白在治疗外周神经损伤中的应用
WO2013053076A1 (en) * 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
MX354598B (es) * 2012-03-30 2018-03-12 Acorda Therapeutics Inc Uso de neuregulina para tratar lesion de nervio periferico.
CA2904055A1 (en) * 2013-03-06 2014-09-12 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure
WO2014187342A1 (en) 2013-05-22 2014-11-27 Zensun (Shanghai) Science & Technology, Ltd. Extended Release of Neuregulin for Treating Heart Failure
CN104758922A (zh) 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
CN105561298A (zh) * 2014-10-17 2016-05-11 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
MA42936A (fr) 2015-09-25 2018-08-01 Douglas B Sawyer Procédé de traitement de blessures cardiaques
EP3445386B1 (en) * 2016-04-19 2020-08-26 Leibniz-Institut für Alternsforschung - Fritz-Lipmann-Institut e.V. (FLI) Neuregulin for the treatment and/or prevention of tumors of the nervous system
CN110835368A (zh) * 2018-08-15 2020-02-25 上海泽生科技开发股份有限公司 神经调节蛋白多肽片段及其用途
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
EP4032901A4 (en) * 2019-09-16 2023-10-25 Zensun (Shanghai) Science & Technology, Co., Ltd. RECOMBINANT HUMAN NEUREGULIN DERIVATIVES AND THEIR USE
WO2023070078A1 (en) * 2021-10-22 2023-04-27 The Research Institute At Nationwide Children's Hospital Neuregulin for protection against respiratory viral infection and post-viral disease

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115554B1 (en) * 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US7037888B1 (en) 1992-04-03 2006-05-02 Acorda Therapeutics, Inc. Methods for treating muscle diseases and disorders
US6087323A (en) 1992-04-03 2000-07-11 Cambridge Neuroscience, Inc. Use of neuregulins as modulators of cellular communication
US5811098A (en) * 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
US6136558A (en) * 1997-02-10 2000-10-24 Genentech, Inc. Heregulin variants
US6051401A (en) 1998-07-28 2000-04-18 Bayer Corporation Methods and constructs for protein expression
SI1115417T1 (sl) 1998-09-25 2006-08-31 Cubist Pharm Inc Uporaba daptomicina
AUPP785098A0 (en) * 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) * 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CN1138785C (zh) * 1999-06-04 2004-02-18 周明东 生长因子神经调节蛋白及其类似物的新应用
EP1267913A2 (en) 1999-11-12 2003-01-02 EntreMed, Inc. Methods for administration of therapeutic agents on an antiangiogenic schedule
IL153052A0 (en) 2000-05-23 2003-06-24 Cenes Pharmaceuticals Inc Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
CU23157A1 (es) * 2001-01-03 2006-07-18 Ct Ingenieria Genetica Biotech COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL
WO2003061571A2 (en) 2002-01-18 2003-07-31 Chiron Corporation Combination il-2/anti-herz antibody therapy for cancers characterized by overexpression of the her2 receptor protein
AU2002304965A1 (en) * 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
WO2006087419A2 (en) * 2005-02-18 2006-08-24 Orion Corporation A method for administering levosimendan
AU2006227879A1 (en) 2005-03-23 2006-09-28 Pfizer Products Inc. Therapy of prostate cancer with CTLA4 antibodies and hormonal therapy
US7776817B2 (en) 2005-09-02 2010-08-17 Morehouse School Of Medicine Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue and as regulators of neuronal stem cell migration
US20070213264A1 (en) * 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
US20070190127A1 (en) * 2005-12-30 2007-08-16 Mingdong Zhou Extended release of neuregulin for improved cardiac function
EP2262527B1 (en) 2008-02-29 2016-08-03 Acorda Therapeutics, Inc. Compositions for achieving desired glial growth factor 2 plasma levels
CN104623633A (zh) 2008-07-17 2015-05-20 阿索尔达治疗公司 用于治疗或预防心力衰竭的神经调节蛋白或其亚序列的治疗性施剂
CN104984322B (zh) 2009-10-14 2020-09-11 阿寇达医疗有限公司 神经调节蛋白在治疗外周神经损伤中的应用
WO2012021818A2 (en) 2010-08-13 2012-02-16 Georgetown University Ggf2 and methods of use
MX354598B (es) 2012-03-30 2018-03-12 Acorda Therapeutics Inc Uso de neuregulina para tratar lesion de nervio periferico.

Also Published As

Publication number Publication date
US20160113999A1 (en) 2016-04-28
CN107019794B (zh) 2021-03-12
JP2015129137A (ja) 2015-07-16
JP5797112B2 (ja) 2015-10-21
US20180280477A1 (en) 2018-10-04
AU2015202877A1 (en) 2015-06-18
US20130324466A1 (en) 2013-12-05
RU2011105821A (ru) 2012-08-27
AU2009292216A1 (en) 2010-03-18
PL2320933T3 (pl) 2018-07-31
US11235031B2 (en) 2022-02-01
CA2731113A1 (en) 2010-03-18
CN104623633A (zh) 2015-05-20
AU2017203528A1 (en) 2017-06-15
US9956266B2 (en) 2018-05-01
DK2320933T3 (en) 2018-04-16
ES2763184T3 (es) 2020-05-27
JP2022023208A (ja) 2022-02-07
PL3338791T3 (pl) 2020-04-30
JP2019196370A (ja) 2019-11-14
CN102159236A (zh) 2011-08-17
HK1256637A1 (en) 2019-09-27
EP2320933A1 (en) 2011-05-18
EP3338791A1 (en) 2018-06-27
JP2017200949A (ja) 2017-11-09
EP3338791B1 (en) 2019-09-18
RU2020111236A3 (OSRAM) 2021-09-21
CN107019794A (zh) 2017-08-08
EP3632459A1 (en) 2020-04-08
JP6189879B2 (ja) 2017-08-30
WO2010030317A2 (en) 2010-03-18
RU2536938C2 (ru) 2014-12-27
AU2009292216B2 (en) 2015-03-05
RU2698090C2 (ru) 2019-08-22
JP2011528353A (ja) 2011-11-17
RU2020111236A (ru) 2021-09-21
RU2719199C1 (ru) 2020-04-17
ES2664394T3 (es) 2018-04-19
RU2014141514A (ru) 2016-05-10
EP2320933A4 (en) 2013-02-27
EP2320933B1 (en) 2017-12-27
US20110166068A1 (en) 2011-07-07
MX2011000696A (es) 2011-07-29
MX384378B (es) 2025-03-14
BRPI0916442A2 (pt) 2018-06-19
US20200009228A1 (en) 2020-01-09
US9198951B2 (en) 2015-12-01
AU2015202877B2 (en) 2017-03-09

Similar Documents

Publication Publication Date Title
DK3338791T3 (da) Terapeutisk dosering af en neuregulin i behandling eller profylaxis af hjertesvigt
DK2448637T4 (da) Anvendelse af et phytocannabinoid eller en kombination af phytocannabinoider i behandling af epilepsi
DK2222272T3 (da) Behandling af luftvejssygdom
NO2019010I1 (no) Eravasyklin eller farmasøytisk akseptable salter derav
CY2014006I2 (el) Μεθοδοι θεραπευτικης αγωγης χρησιμοποιωντας γλυκοπεγκυλιωμενο g-csf
DK2488242T3 (da) Medicinsk indåndingsmaske
RU2557654C3 (ru) Терапевтические агенты для снижения уровней паратиреоидного гормона
DK3967274T3 (da) Hjerteklapanordninger med stent
DK2808024T3 (da) Bifidobakterier til behandling af kongestiv hjerteinsufficiens
BRPI1011441A2 (pt) cinta corporal terapeutica
HRP20170972T1 (hr) Kombinacijska terapija afukoziliranog cd20-protutijela s bendamustinom
HUE045367T2 (hu) Kombinált terápia diabétesz kezelésére
DK2452281T3 (da) Fremgangsmåde til at forudsige virkningen af lægemidler i en patient
DK2538986T3 (da) Intraartikulært supplement til anvendelse til behandling af ledsygdomme og -skader
EP2247297A4 (en) THERAPEUTIC TREATMENT OF LUNG DISEASES
DK2252317T3 (da) Behandling af makuladegeneration
ZA201308391B (en) Use of cathepsin k inhibition for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure
EP2496194A4 (en) EXOTHERMIC NATURAL THERAPEUTIC MASSAGE SHELLS
DK3211005T3 (da) Terapeutisk anvendelse af specifik ligand i msrv-associerede sygdomme
PL2320878T3 (pl) Monoterpeny do leczenia chorób dróg oddechowych, w szczególności chorób oskrzelowo-płucnych
FI20096402A0 (fi) Veriryhmästatuksen käyttö II
DK2323686T3 (da) Adiponectin til behandling af lungesygdom
BRPI1013903A2 (pt) tratamentos terapêuticos utilizando centaquina
BRPI1009322A2 (pt) dose de ave5026 para o tratamento de tromboembolia venosa em pacientes com deficiência renal grave
EP2350264A4 (en) TREATMENT OF CHRONIC INFLAMMATION OF THE RESPIRATORY TRACT